According to Zacks, “Iovance Biotherapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. Iovance Biotherapeutics Inc., formerly known as Lion Biotechnologies Inc., is based in SAN CARLOS, United States. “
IOVA has been the topic of a number of other research reports. Chardan Capital restated a “buy” rating and issued a $33.00 price objective on shares of Iovance Biotherapeutics in a report on Thursday, November 21st. ValuEngine lowered shares of Iovance Biotherapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, December 3rd. Stifel Nicolaus initiated coverage on Iovance Biotherapeutics in a research report on Monday, September 30th. They issued a “buy” rating and a $27.00 price target on the stock. BidaskClub downgraded Iovance Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, January 8th. Finally, JMP Securities began coverage on Iovance Biotherapeutics in a research note on Wednesday, December 18th. They issued an “outperform” rating and a $38.00 price target on the stock. One investment analyst has rated the stock with a sell rating, two have given a hold rating and twelve have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $31.73.
Iovance Biotherapeutics (NASDAQ:IOVA) last released its earnings results on Monday, November 4th. The biotechnology company reported ($0.40) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.39) by ($0.01). As a group, analysts predict that Iovance Biotherapeutics will post -1.5 earnings per share for the current year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in IOVA. Coastal Investment Advisors Inc. boosted its stake in shares of Iovance Biotherapeutics by 2.9% in the 3rd quarter. Coastal Investment Advisors Inc. now owns 29,390 shares of the biotechnology company’s stock worth $534,000 after buying an additional 815 shares during the last quarter. Strs Ohio raised its holdings in Iovance Biotherapeutics by 0.7% in the 3rd quarter. Strs Ohio now owns 127,800 shares of the biotechnology company’s stock worth $2,325,000 after purchasing an additional 900 shares during the period. Ladenburg Thalmann Financial Services Inc. raised its holdings in Iovance Biotherapeutics by 14.9% in the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 7,700 shares of the biotechnology company’s stock worth $189,000 after purchasing an additional 1,000 shares during the period. Tower Research Capital LLC TRC purchased a new position in Iovance Biotherapeutics during the second quarter valued at $29,000. Finally, Tocqueville Asset Management L.P. lifted its position in Iovance Biotherapeutics by 1.2% during the third quarter. Tocqueville Asset Management L.P. now owns 128,605 shares of the biotechnology company’s stock valued at $2,341,000 after purchasing an additional 1,550 shares in the last quarter. 98.10% of the stock is currently owned by hedge funds and other institutional investors.
About Iovance Biotherapeutics
Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma.
Read More: Why do earnings reports matter?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.